OncoMatch/Clinical Trials/NCT06343064
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Is NCT06343064 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Vebreltinib and PLB1004 for non-small-cell lung cancer.
Treatment: Vebreltinib · PLB1004 — Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
EGFR mutations, including exon 19 deletion and exon 21 L858R
Required: EGFR L858R
EGFR mutations, including exon 19 deletion and exon 21 L858R
Required: MET overexpression
C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI
Required: MET amplification
C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI
Excluded: ALK mutation
There are mutations of ALK
Excluded: ROS1 mutation
There are mutations of ... ROS1
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor
C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI
Cannot have received: MET inhibitor
Previous treatment with MET inhibitors
Cannot have received: HGF-targeted therapy
Previous treatment with ... HGF-targeted therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify